Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib Modulation of Hyperinflammation in Moderate and Severe COVID-19
NCT04830735Phase 2Withdrawn
- Sponsor
- University of Southern California
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in coronavirus disease 2019 (COVID-19), sponsored by University of Southern California. Planned start Aug 2022; status: withdrawn.
02
Drugs
dasatinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04830735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830735.